Dr. Margaret Redfield is a distinguished cardiologist and internationally recognized expert in heart failure management at Mayo Clinic. She serves as a consultant in Cardiovascular Diseases, director of the Circulatory Failure program, and professor in Cardiology at Mayo Clinic College of Medicine. Following her residency in Cardiovascular Disease at Mayo School of Graduate Medical Education in 1991, she developed a distinguished career focused on complex cardiovascular pathologies. Her clinical leadership spans Mayo Clinic's heart failure programs, where she has established comprehensive care pathways for patients with advanced cardiac conditions.
Dr. Redfield's research primarily focuses on heart failure with preserved ejection fraction, a condition affecting millions of patients worldwide with limited treatment options. As co-director of the Mayo Clinic Cardiorenal Research Laboratory, she has pioneered investigations into the intricate relationship between cardiac and renal dysfunction in heart failure patients. Her systematic studies on amyloid cardiomyopathy, diastolic heart failure mechanisms, and natriuretic peptide dynamics have significantly advanced diagnostic criteria and therapeutic approaches in clinical practice. Through expertise in echocardiography and innovative remote monitoring techniques, she has developed refined methods for assessing cardiac function and tracking disease progression in diverse patient populations.
Dr. Redfield's substantial contributions to cardiovascular medicine were recognized with the American Heart Association Population Research Prize for her epidemiological work in heart failure. She maintains an active clinical practice in Mayo's heart failure clinic and advanced heart failure hospital service, seamlessly integrating research findings into patient care protocols. As a dedicated educator, she mentors cardiology fellows and junior faculty, shaping the next generation of heart failure specialists through rigorous training programs. Her ongoing research continues to explore pulmonary hypertension in heart failure and refine risk stratification strategies to improve long-term patient outcomes across diverse demographic groups.
